SCHEMBL30265193

SCHEMBL30265193

NCCCC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GHSR Q92847 4/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ MPO P05164 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ BLM P54132 1/20 0.55
▸ PMP22 Q01453 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ HIF1A Q16665 1/20 0.55
▸ PRMT1 Q99873 1/20 0.53
▸ ACE P12821 2/20 0.52
▸ UTS2R Q9UKP6 1/20 0.51
▸ MC4R P32245 2/20 0.50
▸ MC5R P33032 1/20 0.50
▸ MC3R P41968 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29603261 0.96 KDM4E (0.59) GHSRKDM4EMEN1LMNAMPO
SCHEMBL31468788 0.94 GHSR (0.61) GHSRKDM4EMEN1LMNAMPO
SCHEMBL1387764 0.94 KDM4E (0.61) GHSRKDM4EMEN1LMNAMPO
SCHEMBL29382469 0.94 KDM4E (0.61) GHSRKDM4EMEN1LMNAMPO
SCHEMBL29404993 0.94 KDM4E (0.61) GHSRKDM4EMEN1LMNAMPO
SCHEMBL3048070 0.94 KDM4E (0.61) GHSRKDM4EMEN1LMNAMPO
SCHEMBL29721506 0.94 KDM4E (0.61) GHSRKDM4EMEN1LMNAMPO
SCHEMBL1711405 0.94 KDM4E (0.61) GHSRKDM4EMEN1LMNAMPO
SCHEMBL14906252 0.94 KDM4E (0.61) GHSRKDM4EMEN1LMNAMPO
SCHEMBL27542236 0.94 KDM4E (0.61) GHSRKDM4EMEN1LMNAMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4392440-A2 COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS River 2 Renal Corp. (US) 2024-07-03 — — EP disclosed
WO-2023028008-A2 COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS RIVER 2 RENAL CORP. (US) 2023-03-02 — — WO disclosed
Send feedback